Northeast Pharmaceutical Group's (SHE:000597) subsidiary, Dongyao Group Shenyang Shide, obtained a drug registration certificate from China's National Medical Products Administration for the levocarnitine oral solution, according to a Shenzhen Stock Exchange disclosure on Thursday.

The drug is used for the treatment of primary systemic carnitine deficiency and for the short-term and long-term treatment of secondary carnitine deficiency caused by congenital metabolic disorders.

The certificate is valid until March 31, 2030, the pharmaceutical company said.